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Proteasome inhibitors are key parts of our armamentarium against multiple myeloma, but the disease can
become resistant through poorly defined mechanisms. In this issue of Cancer Cell, Leung-Hagesteijn and
colleagues describe XBP1s subpopulations of tumor cells that are resistant to bortezomib andmay account
for therapeutic failures in the clinic.Multiple myeloma is a clonal prolifera-
tion of neoplastic plasma cells that can
present clinically with hypercalcemia,
renal insufficiency, anemia, bony lesions,
bacterial infections, hyperviscosity, and
amyloidosis. Worldwide, approximately
86,000 patients will be diagnosed each
year with myeloma, which, in many areas,
makes it the secondmost common hema-
tologic malignancy, while about 63,000
patients die every year from disease-
related complications (Becker, 2011). In
the United States, due to an aging popu-
lace, it is anticipated that the number of
cases of myeloma will grow by 57%
between 2010 and 2030 (Smith et al.,
2009), ranking myeloma behind only
stomach and liver cancer in the rate of
growth of new cases. These facts indicate
thatmultiplemyeloma is, andwill continue
to be, a significant source of morbidity
and mortality. Fortunately, a number of
advances over the past decade have
dramatically improved patient outcomes.
Among these are the advent of novel
chemotherapeutics, including the immu-
nomodulatory agents thalidomide, lenali-
domide, and pomalidomide, and the pro-
teasome inhibitors (Moreau et al., 2012)
bortezomib and carfilzomib. All of these
drugs have garnered regulatory approvals
and are used in patients with newly
diagnosed, relapsed, or relapsed/refrac-
tory disease and have contributed to a
doubling of the median overall survival in
many populations. This has been fueled
by a greater understanding of the pathobi-
ology ofmyelomaandby thedevelopment
of more physiologically relevant preclini-
cal models, allowing for greater success
in translating laboratory concepts intopatient-focused therapies. Indeed, a
number of the most potent combination
regimens in use have been rationally
developed based on studies of the mech-
anisms of action of these drug classes
(Mahindra et al., 2012).
Despite these significant advances,
patients are currently treated on an
empiric basis, typically with the regimens
that have the highest response rates
to which they have access, rather than
based on the principles of precision med-
icine (Mendelsohn, 2013). The protea-
some inhibitors bortezomib and carfilzo-
mib as single agents in the relapsed and
refractory settings both have response
rates of approximately 25%, indicating a
role for innate or primary resistance in
modulating their activity. Response rates
and, even more importantly, response
durability can be improved by using
them earlier in the disease process and
incorporating them into combination regi-
mens. However, no clinically relevant bio-
markers have been validated that would
allow practitioners to prospectively iden-
tify patients with disease that ismost likely
to respond to proteasome inhibition, and
the same is true for the immunomodula-
tory drugs. In addition, even in patients
whose disease initially responds, resis-
tance to proteasome inhibitor-based ther-
apy emerges in many, indicating a role for
acquired or secondary resistance through
incompletely understood mechanisms.
As a result, some patients are exposed
to the toxicities of these agents without
a benefit, delaying their access to more
effective options, and wasting precious
healthcare resources. Clinically, these
factors contribute to the natural historyCancer Cell 24, Sof the disease, which follows a course
characterized by multiple relapses and
decreasing durations of benefit with
each subsequent line of therapy.
The work of Leung-Hagesteijn et al.
(2013) in this issue of Cancer Cell may,
however, begin to change the current
status quo. Early attempts to identify
mechanisms of innate bortezomib resis-
tance implicated a role for overexpression
of proteasome genes and especially of
PSMD4 (Shaughnessy et al., 2011). Later,
studies of acquired resistance models
suggested mutations of the b5 protea-
some subunit targeted by bortezomib
were involved. However, these b5 muta-
tions were subsequently not detected
in patient samples, as indicated in the
introduction by Leung-Hagesteijn et al.
(2013). More recently, induction of
signaling through the insulin-like growth
factor (IGF)/IGF-1 receptor pathway has
been implicated in acquired resistance
(Kuhn et al., 2012), and clinical trials to
test this possibility are planned. Finally,
upregulation of a cluster ofNRF2oxidative
stress response genes, including CHOP
(DDIT3), was identified as a possible
resistance signature in studies of murine
myeloma models and clinically anno-
tated gene expression profiling data
sets (Stessman et al., 2013).
In contrast, Leung-Hagesteijn et al.
(2013) provide a different perspective
starting from kinome-wide RNA interfer-
ence studies intended to identify modu-
lators of proteasome inhibitor sensitivity.
They report that suppression of inositol-
requiring enzyme 1 (IRE1) and its down-
stream effector, X-box binding protein 1
(XBP1), was associated with bortezomibeptember 9, 2013 ª2013 Elsevier Inc. 275
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Figure 1. Model of Proteasome Inhibitor Resistance
Patients with multiple myeloma may have a number of neoplastic subpopulations, including B cells,
activated B cells, pre-plasmablasts, plasmablasts, and plasma cells. B cells are typically cluster differ-
entiation antigen 20+ (CD20+)/CD27+/paired box 5+ (PAX5+) and do not have spliced X-box binding pro-
tein 1 message (XBP-1 s), whereas activated B cells are similar but express lower levels of CD20 and
can be CD30+. Neither B cells nor activated B cells are involved in substantial immunoglobulin synthe-
sis, and both therefore have relatively low levels of proteasome-assisted, endoplasmic reticulum-asso-
ciated protein degradation (ERADlo). Pre-plasmablasts are probably CD27lo/PAX5lo/CD30+/XBP-1 s,
express the interleukin 6 receptor (IL-6R+), produce low levels of monoclonal protein (Y), and therefore
have modest levels of ERAD activity (ERADmod). Plasmablasts are CD38+/CD138lo/IL-6R+/XBP-1 s+,
secrete increased levels of monoclonal protein, and therefore have higher ERAD activity (ERADhi).
Finally, terminally differentiated plasma cells are CD38+/CD138+/IL-6R+/XBP-1 s+, produce high levels
of monoclonal protein, and have the highest levels of ERAD activity. These phenotypic characteristics
are taken from the work of Leung-Hagesteijn et al. (2013) and from other literature sources. Plasma-
blasts and plasma cells are sensitive to proteasome inhibitors such as bortezomib because of their
high level of immunoglobulin synthesis, leading to high levels of ERAD-related stress, which triggers
dependence on the unfolded protein response (UPR). B cells, activated B cells, and pre-plasmablasts,
in part because they are XBP-1 s, produce less immunoglobulin and are therefore less susceptible.
Treatment with bortezomib eradicates plasmablasts and plasma cells, which initially may make up
the bulk of the tumor compartment and results in elimination of the monoclonal protein marker. How-
ever, B cells, activated B cells, and pre-plasmablasts, which initially are a minor component of the tumor
compartment, survive. After expansion of these cells, patients may then develop clinical relapses that
are bortezomib-resistant with disease that is hypo- or nonsecretory and may require a different treat-
ment approach.
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lenges a current dogma, because IRE1
and XBP1 make up one arm of the
unfolded protein response (UPR). Indeed,
UPR activation was felt to represent an
adaptation to proteasome-assisted endo-
plasmic reticulum-associated degrada-
tion (ERAD), which causes ER stress in
plasma cells due to their large loads
of misfolded proteins. These IRE1lo and
XBP1lo cells showed lower expression
of plasma cell maturation markers, lower
immunoglobulin synthesis, and lower
levels of UPR activation, consistent with
a lower stress level and proteasome276 Cancer Cell 24, September 9, 2013 ª201load, which would make them resis-
tant to proteasome inhibitors. Moreover,
plasma cell maturation markers were
enriched in samples from patients who
responded to bortezomib-based therapy
and reduced in those with no response
to bortezomib. Finally, analysis of patient
samples revealed the presence of up to
five tumor cell subpopulations, includ-
ing B cells, activated B cells, pre-plas-
mablasts, plasmablasts, and plasma
cells, which would be expected to
have different sensitivities to bortezo-
mib (Figure 1). Consistent with this possi-
bility, myeloma B cell and pre-plasma-3 Elsevier Inc.blast progenitors were found to survive
proteasome inhibition and be enriched
in samples that were refractory to
bortezomib.
These findings have a number of key
implications for innate and acquired
proteasome inhibitor resistance. First,
they suggest that the seeds for bortezo-
mib resistance, and cross-resistance
with other proteasome inhibitors, are
already present in perhaps all patients
and that this phenotype will inevitably
emerge through the attrition of bortezo-
mib-sensitive plasmablasts and plasma
cells (Figure 1). Second, they support the
possibility that gene expression profiling
or whole genome sequencing to identify
the baseline proportion of these progeni-
tor cells present in patients prior to initia-
tion of therapy may predict the extent of
benefit to be expected from bortezomib.
Finally, they imply that potentially cura-
tive strategies will need to target both
the committed plasma cells and the pro-
genitor, or stem cell-like cells.
While these hypotheses are being
tested, the current findings will also
need to be validated in a wider array of
primary samples and additional gene
expression profiling data sets. One ques-
tion that needs to be answered is whether
the same proteasome inhibitor-resistant
progenitor cells survive therapy with
bortezomib in combination with other
agents. This would be especially of inter-
est for the combination of bortezomib
and lenalidomide, because the latter
may target clonogenic side-population
cells (Jakubikova et al., 2011), and this
regimen is one of our current standards
of care against myeloma. Another impor-
tant question is whether it would be
possible to induce differentiation of pro-
genitor cells to more committed plasma
cells, such as through epigenetic thera-
pies, to enhance or restore proteasome
inhibitor sensitivity. Finally, it is likely
that multiple mechanisms contribute to
the development of the proteasome in-
hibitor-resistant phenotype. For example,
while the current studies indicate that
cells with a decreased proteasome load
are resistant, it is also possible that
changes that enhance plasma cell pro-
teasome capacity would antagonize the
beneficial effects of bortezomib and car-
filzomib. Taken together, however, these
findings do provide an important direc-
tion for future preclinical and clinical
Cancer Cell
Previewsstudies that will hopefully bring us to
the point that we can apply precision
medicine to the therapy of multiple
myeloma.
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Oncogenic activation of Ras proteins due tomissensemutations is frequently detected in human cancers but
rarely in breast cancer. In this issue of Cancer Cell, McLaughlin and colleagues report that ablation of the
GasGAP gene, RASAL2, is an alternative mechanism by which Ras becomes activated in breast cancer.Ras GTPases are essential components
of signaling pathways that emanate cues
from cell surface receptors to regulate
diverse cellular processes, including cell
cycle progression, cell survival, actin
cytoskeletal organization, cell polarity
and movement, as well as vesicular and
nuclear transport (Vigil et al., 2010). Ras
proteins (H-Ras, N-Ras, and K-Ras),
together with their two key regulators
(guanine nucleotide exchange factors/
GEFs and GTPase-activating proteins/
GAPs), constitute cellular binary switches
that cycle between ‘‘on’’ and ‘‘off’’ confor-
mations conferred by the loading of
GTP or GDP, respectively. The transition
between the active GTP-bound and inac-
tive GDP-bound states of Ras GTPases is
controlled by GEFs, which promote the
activation of Ras proteins by stimulatingGDP for GTP exchange, and GAPs, which
terminate the activation status by acceler-
ating Ras-mediated GTP hydrolysis (Bos
et al., 2007; Tcherkezian and Lamarche-
Vane, 2007). Ras GTPases and cancer
are tightly associated, as high frequency
of mutational activation of Ras proteins
is observed in 33% of human cancers.
The intrinsic GTP hydrolysis activity
of Ras is the predominant target of the
most common somatic mutations that
are found in the oncogenic variants
of RAS alleles (Pylayeva-Gupta et al.,
2011). Specifically, oncogenic substitu-
tion in residue G12 or G13 results in pro-
nounced attenuation of intrinsic GTP
hydrolysis, which leads to the persis-
tence of the GTP-bound state of Ras
and subsequently activates a multitude
of Ras-dependent downstream effectorpathways. Beyond Ras, hyperactivation
of GEFs and functional deregulation,
including suppression and loss-of-func-
tion mutations of GAPs, have also been
suggested to play important roles in can-
cer progression (Vigil et al., 2010).
Despite the prevalence of oncogenic
RAS mutations in human cancers, K-
RAS, H-RAS, and N-RAS are rarely
mutated in breast cancer (Karnoub and
Weinberg, 2008). Nonetheless, the Ras/
ERK pathway is hyperactivated in more
than half of breast cancers and has been
implicated in tumor progression and
recurrence (von Lintig et al., 2000), sug-
gesting that Ras proteins may be more
frequently activated by alternative mech-
anisms in this type of tumors. A new study
by McLaughlin et al. (2013) in this issue of
Cancer Cell uncovers the role of RASAL2,eptember 9, 2013 ª2013 Elsevier Inc. 277
